Search research articles

Search research articles

Related Experiment Videos

Cancer vaccines.

T F Greten¹, E M Jaffee

¹Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|March 10, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treating Hepatobiliary Cancer: The Immunologic Approach.

Digestive diseases (Basel, Switzerland)·2017

Same author

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

International journal of cancer·2016

Same author

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

United European gastroenterology journal·2015

Same author

Methods for retrovirus-mediated gene transfer to tumor cells.

Methods in molecular medicine·2014

Same author

[Diagnosis of and therapy for hepatocellular carcinoma].

Zeitschrift fur Gastroenterologie·2013

Same author

Immunological off-target effects of standard treatments in gastrointestinal cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Cancer vaccines aim to activate the immune system against tumors. Advances in molecular biology and T cell activation are enabling more specific cancer vaccines, showing promise in animal models.

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Cancer immunotherapy has a century-long history with limited success.
Active immunotherapy, including cancer vaccines, is not yet a standard treatment.
Recent progress in molecular biology and T cell activation has spurred new vaccine designs.

Purpose of the Study:

To review advances in cancer vaccine development.
To highlight the use of whole tumor cells and genetic modification in current vaccine strategies.
To discuss future directions in antigen-specific cancer vaccines.

Main Methods:

Review of recent advances in cancer immunotherapy research.
Analysis of current clinical vaccine approaches using genetically modified tumor cells.

Related Experiment Videos

Discussion of molecular biology techniques and T cell activation mechanisms.

Main Results:

Improved systemic antitumor immune responses observed in animal models.
Current clinical trials focus on genetically modified whole cancer cells.
Tumor cells are identified as the optimal source for immunizing antigens.

Conclusions:

Advances in technology and immunology have led to more specific cancer vaccine designs.
Genetically modified whole cancer cell vaccines are a current focus in clinical research.
Future development of targeted antigen-specific vaccines holds promise for cancer treatment.